Alentis is a clinical-stage company building on the discovery that CLDN1 is a previously unexplored target with a unique mechanism of action in the pathology of immune evasive tumors and fibrosis in chronic diseases.
Claudin-1 (CLDN1) is a member of the tight junction protein family. During disease pathogenesis, CLDN1 expression is upregulated and exposed outside of the tight junction. Exposed CLDN1 drives remodeling and stiffening of the extracellular matrix (ECM) as well as carcinogenic and fibrogenic signaling in different organs.
Alentis’ pioneering approach harnesses the high specificity and potency of its anti-CLDN1 monoclonal antibodies to target exposed non-junctional CLDN1, revert pathogenesis associated with ECM remodeling and fibrosis, and sensitize solid tumors to immuno-oncologic and chemotherapeutic medication.